KRAS and non-small cell lung carcinoma: Smit and colleagues reported in an early phase trial 4 partial responses and 6 stabilisations of diseasein 10 NSCLC patients, harboring the KRAS mutation treated with sorafenib after failure of chemotherapy [65].